Table 3:

When should genetic risk assessment be performed?^*

Consensus question	Yes	No
In the absence of syndromic manifestations, should an individual with bilateral or multifocal renal tumors have a histologic diagnosis prior to genetic risk assessment?	57%	43%
In the absence of syndromic manifestations, should an individual with a solitary renal tumor with one or more hereditary risk factors have a histologic diagnosis prior to genetic risk assessment?	41%	59%
In the absence of syndromic manifestations, should an individual with localized, bilateral or multifocal renal tumors have genetic risk assessment prior to management?	79%	21%
In the absence of syndromic manifestations, should an individual with a localized, solitary renal tumor with one or more hereditary risk factors have genetic risk assessment prior to management?	59%	41%
In an individual with a localized renal lesion less than 3 cm and strong suspicion for a hereditary cancer syndrome, should genetic risk assessment be performed prior to management?	93%	7%
In metastatic disease that doesn’t require urgent treatment, when there is concern for hereditary form of RCC, do you think genetic risk assessment should be done before management is initiated?	48%	52%
In a patient with a renal tumor and skin lesion(s) resembling those associated with a renal cancer syndrome, should a skin biopsy be required to guide genetic risk assessment?	14%	86%

^*Statements in bold represent those with reached consensus